We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

37 hedge funds and large institutions have $70.8M invested in Sinovac Biotech, Ltd in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

9% more funds holding

Funds holding: 34 → 37 (+3)

8% less capital invested

Capital invested by funds: $77.1M → $70.8M (-$6.33M)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

Holders
37
Holders Change
+3
Holders Change %
+8.82%
% of All Funds
0.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
13
Closed
6
Calls
$119K
Puts
–
Net Calls
+$119K
Net Calls Change
-$6K

Top Buyers

Rank Fund Capital Flow
1
PRCM
Pine River Capital Management
Minnesota
+$2.22M
2
ACP
Acuta Capital Partners
California
+$812K
3
Renaissance Technologies
Renaissance Technologies
New York
+$377K
4
CS
Credit Suisse
Switzerland
+$370K
5
GP
GLG Partners
United Kingdom
+$354K

Top Sellers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
-$4.07M
2
Deutsche Bank
Deutsche Bank
Germany
-$432K
3
OTC
Opera Trading Capital
France
-$230K
4
VAM
Verity Asset Management
North Carolina
-$175K
5
GCP
GSA Capital Partners
United Kingdom
-$155K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$31.1M -$73.7K -12,023 -0.2%
O
2
OrbiMed
New York
$15.8M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$8.28M +$377K +61,500 +5%
PRCM
4
Pine River Capital Management
Minnesota
$3.25M +$2.22M +362,856 +196%
USAA
5
United Services Automobile Association
Texas
$2.13M – – –
First Manhattan
6
First Manhattan
New York
$2M -$4.07M -663,200 -66%
Citigroup
7
Citigroup
New York
$1.68M – – –
FIM
8
Freedom Investment Management
Connecticut
$1.35M +$60K +9,794 +4%
ACP
9
Acuta Capital Partners
California
$786K +$812K +132,503 New
Invesco
10
Invesco
Georgia
$676K +$49.5K +8,081 +8%
Deutsche Bank
11
Deutsche Bank
Germany
$499K -$432K -70,406 -46%
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$411K -$13.5K -2,200 -3%
CS
13
Credit Suisse
Switzerland
$358K +$370K +60,343 New
GP
14
GLG Partners
United Kingdom
$343K +$354K +57,800 New
Two Sigma Investments
15
Two Sigma Investments
New York
$338K -$1.64K -267 -0.5%
Morgan Stanley
16
Morgan Stanley
New York
$298K -$15.3K -2,500 -5%
PAM
17
Panagora Asset Management
Massachusetts
$254K +$11.8K +1,929 +5%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$240K -$48.4K -7,900 -16%
OAC
19
OMERS Administration Corp
Ontario, Canada
$212K +$11.6K +1,900 +6%
GC
20
Guggenheim Capital
Illinois
$147K -$10.2K -1,672 -6%
TC
21
TFS Capital
Pennsylvania
$146K +$70.2K +11,451 +87%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$137K – – –
State Street
23
State Street
Massachusetts
$100K +$104K +16,912 New
SIM
24
Spark Investment Management
New York
$61K +$63.1K +10,300 New
GBBWRPM
25
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
$59K – – –
1
2

SVA Hedge Fund Activity: Q2 2016 in Review

37 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2016, worth a combined $70.8M — down 8.2% from $77.1M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SVA positions and 6 closed out — a net gain of 3 holders — while 7 added to existing stakes and 13 trimmed.

The largest buyer was Pine River Capital Management, adding an estimated $2.22M. The largest seller was First Manhattan, cutting an estimated $4.07M.

  • 37 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2016, up from 34 in Q1 2016.
  • Funds reported $70.8M of Sinovac Biotech, Ltd stock for Q2 2016, down 8.2% quarter-over-quarter.
  • 9 funds opened new Sinovac Biotech, Ltd positions in Q2 2016 and 6 closed out, a net change of +3 holders.
  • The largest Sinovac Biotech, Ltd buyer in Q2 2016 was Pine River Capital Management, an estimated $2.22M added.
  • The largest Sinovac Biotech, Ltd seller in Q2 2016 was First Manhattan, an estimated $4.07M sold.

Based on aggregated 13F filings for Q2 2016.